JAVELIN Merkel 200: Results of Phase II Study for Merkel Cell Carcinoma - 102147

Spotlight
Video

JAVELIN Merkel 200: Results of Phase II Study for Merkel Cell Carcinoma

aacr2017 has 92 videos Subscribe Here

Loading........
Description: Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of his current research, a phase II study which involved a newly FDA-approved drug, avelumab, in patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.
Shared By : aacr2017
Posted on : 04/27/17
Added : 1 year ago